In last trading session, Moleculin Biotech, Inc. (NASDAQ:MBRX) saw 1,483,673 shares changing hands with its beta currently measuring 2.12. Company’s recent per share price level of $0.98 trading at $0.02 or 1.69% at ring of the bell on the day assigns it a market valuation of $60.98 Million. That closing price of MBRX’s stock is at a discount of -101.02% from its 52-week high price of $1.97 and is indicating a premium of 67.04% from its 52-week low price of $0.323. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.39 Million shares which gives us an average trading volume of 2.06 Million if we extend that period to 3-months.
For Moleculin Biotech, Inc. (MBRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.7. Splitting up the data highlights that, out of 3 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 3 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.09 in the current quarter.
Moleculin Biotech, Inc. (NASDAQ:MBRX) trade information
Upright in the green during last session for gaining 1.69%, in the last five days MBRX remained trading in the green while hitting it’s week-highest on Monday, Jan 11 when the stock touched $1.09 price level, adding 10.44% to its value on the day. Moleculin Biotech, Inc.’s shares saw a change of 22.47% in year-to-date performance and have moved 10.93% in past 5-day. Moleculin Biotech, Inc. (NASDAQ:MBRX) showed a performance of 20.52% in past 30-days. Number of shares sold short was 2.43 Million shares which calculate 1.18 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $3.33 to the stock, which implies a rise of 239.8% to its current value. Analysts have been projecting $2 as a low price target for the stock while placing it at a high target of $5. It follows that stock’s current price would jump +410.2% in reaching the projected high whereas dropping to the targeted low would mean a loss of 104.08% for stock’s current value.
Moleculin Biotech, Inc. (MBRX) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -20.7% during past 5 years. In 2021, company’s earnings growth rate is likely to be around 29.3% while estimates for its earnings growth in next 5 years are of 0%
Moleculin Biotech, Inc. (NASDAQ:MBRX)’s Major holders
Insiders are in possession of 11.16% of company’s total shares while institution are holding 22.85% percent of that, with stock having share float percentage of 25.71%. Investors also watch the number of corporate investors in a company very closely, which is 29 institutions for Moleculin Biotech, Inc. that are currently holding shares of the company. Renaissance Technologies, LLC is the top institutional holder at MBRX for having 891.14 Thousand shares of worth $724.23 Thousand. And as of September 29, 2020, it was holding 1.43% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 625.98 Thousand shares on September 29, 2020. The number of shares represents firm’s hold over 1% of outstanding shares, having a total worth of $508.73 Thousand.
On the other hand, Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of September 29, 2020, the former fund manager was holding 563784 shares of worth $458.19 Thousand or 0.9% of the total outstanding shares. The later fund manager was in possession of 188.18 Thousand shares on November 29, 2020, making its stake of worth around $146.78 Thousand in the company or a holder of 0.3% of company’s stock.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.